PD-L1 Expression in NSCLC: Clouds in a Bright Sky

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed Death-Ligand 1 (PD-L1) is a key target for immune checkpoint inhibitors (CPIs) in cancer therapy.
• Tumoral PD-L1 expression is a recognized, yet imperfect, predictor of CPI response, particularly in lung cancer.
• PD-L1's role in immune resistance is linked to interferon-gamma upregulation by immune cells near tumor cells.

Purpose of the Study:

• To review the molecular mechanisms regulating PD-L1 expression in lung cancer.
• To discuss the limitations of PD-L1 as a predictive biomarker for CPI therapy.
• To explore emerging multimodal/multi-omics biomarker strategies for patient selection.

Main Methods:

• Literature review focusing on molecular mechanisms of PD-L1 expression.
• Analysis of factors influencing PD-L1 modulation (oncogenic pathways, transcriptional/post-transcriptional regulation).
• Discussion of measurement challenges (glycosylation, immunohistochemistry accuracy).

Main Results:

• PD-L1 expression is modulated by multiple factors, leading to potential false positive/negative predictions.
• PD-L1 levels can be unstable during cancer treatment (chemotherapy, TKIs), impacting predictive value.
• Complex regulatory networks and measurement variability challenge PD-L1's sole reliance as a biomarker.

Conclusions:

• Optimizing CPI therapy requires understanding PD-L1's complex regulation and limitations.
• Multimodal and multi-omics biomarker approaches are emerging for improved patient selection.
• Large-scale prospective studies are needed to validate comprehensive PD-L1-enriched biomarker strategies in lung cancer.